Ccnd2 (cyclin D2) - Rat Genome Database

Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Ccnd2 (cyclin D2) Rattus norvegicus
Analyze
Symbol: Ccnd2
Name: cyclin D2
RGD ID: 621083
Description: Enables protein kinase binding activity. Involved in several processes, including cellular response to hormone stimulus; cellular response to testosterone stimulus; and positive regulation of cell population proliferation. Located in nucleus. Used to study transitional cell carcinoma. Biomarker of colon cancer; glaucoma; impotence; nephritis; and renovascular hypertension. Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); carcinoma (multiple); ductal carcinoma in situ; hepatitis B; and liver cancer (multiple). Orthologous to human CCND2 (cyclin D2); PARTICIPATES IN G1/S transition pathway; cell cycle pathway, mitotic; Jak-Stat signaling pathway; INTERACTS WITH (R,R,R)-alpha-tocopherol; 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 17alpha-ethynylestradiol.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: G1/S-specific cyclin-D2; LOC297611; vin-1 proto-oncogene
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Candidate Gene For: Ept5
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.24159,966,883 - 159,989,261 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl4159,962,363 - 159,989,495 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx4166,196,679 - 166,219,054 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.04161,979,585 - 162,001,961 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.04160,613,640 - 160,636,015 (-)NCBIRnor_WKY
Rnor_6.04159,674,885 - 159,697,207 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl4159,674,885 - 159,697,207 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.04231,905,449 - 231,927,999 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.44163,523,817 - 163,546,501 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.14163,768,752 - 163,791,437 (-)NCBI
Celera4148,681,937 - 148,704,301 (-)NCBICelera
Cytogenetic Map4q42NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute myeloid leukemia  (ISO)
bilateral perisylvian polymicrogyria  (ISO)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
Cardiomegaly  (ISO)
Chronic Hepatitis C  (ISO)
colon adenoma  (ISO)
colon cancer  (IEP)
Colonic Neoplasms  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
ductal carcinoma in situ  (ISO)
epilepsy  (ISO)
episodic ataxia type 1  (ISO)
Fibrosis  (ISO)
genetic disease  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
germinoma  (ISO)
glaucoma  (IEP)
granulosa cell tumor  (ISO)
Helicobacter Infections  (ISO)
hepatitis B  (ISO)
hepatocellular carcinoma  (ISO)
hydrocephalus  (ISO)
Hyperphosphatemic Familial Tumoral Calcinosis 1  (ISO)
impotence  (IEP)
invasive lobular carcinoma  (ISO)
Left Ventricular Hypertrophy  (IEP)
liver cancer  (ISO)
liver cirrhosis  (ISO)
Liver Metastasis  (ISO)
lung adenocarcinoma  (ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphoproliferative syndrome 2  (ISO)
Macrocephaly  (ISO)
Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus Syndrome  (ISO)
Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus Syndrome 3  (ISO)
multiple myeloma  (ISO)
Myocardial Ischemia  (ISO)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
nephritis  (IEP)
nephroblastoma  (ISO)
Ovarian Neoplasms  (ISO)
Postaxial Polydactyly, Type A1  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
renovascular hypertension  (IEP)
seminoma  (ISO)
stomach cancer  (ISO)
stomach carcinoma  (ISO)
Testicular Neoplasms  (ISO)
transitional cell carcinoma  (IDA)
type 2 diabetes mellitus  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(R,R,R)-alpha-tocopherol  (EXP)
(S)-nicotine  (ISO)
1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP,ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-butoxyethanol  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,3',5,5'-tetrabromobisphenol A  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-vinylcyclohexene dioxide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
8-Br-cAMP  (ISO)
9,10-anthraquinone  (ISO)
acetamide  (EXP)
acetazolamide  (ISO)
acrylamide  (EXP)
acrylonitrile  (EXP)
acteoside  (ISO)
aflatoxin B1  (ISO)
alachlor  (EXP)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinol  (EXP)
AM-251  (ISO)
ammonium chloride  (EXP)
aniline  (EXP)
antimycin A  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
atrazine  (EXP)
belinostat  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[b]fluoranthene  (ISO)
benzoates  (ISO)
berberine  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bortezomib  (ISO)
butan-1-ol  (ISO)
butanal  (ISO)
Butylbenzyl phthalate  (ISO)
calcitriol  (ISO)
captan  (ISO)
celecoxib  (ISO)
chloropicrin  (ISO)
chlorpyrifos  (ISO)
choline  (EXP,ISO)
chromium(6+)  (EXP,ISO)
chrysene  (ISO)
ciprofibrate  (ISO)
cisplatin  (ISO)
clofibrate  (ISO)
cobalt dichloride  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
corticosterone  (EXP)
crocidolite asbestos  (ISO)
Cuprizon  (EXP)
cyanamide  (ISO)
Cyclopamine  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (ISO)
cypermethrin  (EXP,ISO)
D-glucose  (ISO)
DDT  (ISO)
delta-tocotrienol  (ISO)
desferrioxamine B  (ISO)
dexamethasone  (EXP,ISO)
diarsenic trioxide  (ISO)
dibutyl phthalate  (ISO)
diethanolamine  (EXP,ISO)
diethyl phthalate  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dimethylarsinic acid  (EXP)
dioxygen  (ISO)
disodium selenite  (ISO)
disulfiram  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental selenium  (ISO)
epoxiconazole  (ISO)
ethanol  (EXP,ISO)
everolimus  (ISO)
fenamidone  (ISO)
flutamide  (EXP)
folic acid  (ISO)
folpet  (ISO)
formaldehyde  (ISO)
fucoidan  (ISO)
furan  (EXP)
geldanamycin  (ISO)
genistein  (EXP,ISO)
glucose  (ISO)
hydrogen peroxide  (ISO)
hydroxyurea  (ISO)
indole-3-methanol  (EXP)
indometacin  (ISO)
iodoacetic acid  (ISO)
isobutanol  (ISO)
isoliquiritigenin  (ISO)
L-ascorbic acid  (EXP,ISO)
lamivudine  (ISO)
lead(0)  (ISO)
lead(2+)  (ISO)
letrozole  (ISO)
lipopolysaccharide  (ISO)
lithium atom  (ISO)
lithium chloride  (ISO)
lithium hydride  (ISO)
LY294002  (ISO)
maneb  (EXP)
metformin  (EXP,ISO)
methotrexate  (ISO)
methoxychlor  (EXP,ISO)
methyl methanesulfonate  (ISO)
methylmercury chloride  (ISO)
microcystin-LR  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
Monobutylphthalate  (ISO)
monosodium L-glutamate  (EXP,ISO)
N-acetyl-L-cysteine  (EXP,ISO)
N-methylformamide  (ISO)
nickel atom  (ISO)
nickel dichloride  (ISO)
niclosamide  (ISO)
nicotine  (ISO)
ochratoxin A  (EXP)
orphenadrine  (EXP)
paclitaxel  (ISO)
palbociclib  (ISO)
paracetamol  (ISO)
paraquat  (EXP,ISO)
PCB138  (ISO)
pentanal  (ISO)
perfluorononanoic acid  (ISO)
perfluorooctanoic acid  (ISO)
pevonedistat  (ISO)
phenobarbital  (ISO)
phenylephrine  (EXP)
PhIP  (EXP)
picrotoxin  (EXP)
piperine  (ISO)
pirinixic acid  (ISO)
potassium dichromate  (EXP)
propanal  (ISO)
prostaglandin F2alpha  (EXP)
pyrogallol  (ISO)
quercetin  (ISO)
Rebamipide  (EXP)
resveratrol  (ISO)
rimonabant  (ISO)
ritonavir  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
Salinomycin  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
silicon dioxide  (EXP,ISO)
silver atom  (ISO)
silver(0)  (ISO)
simazine  (ISO)
sirolimus  (EXP,ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (EXP,ISO)
sorafenib  (ISO)
sterigmatocystin  (EXP)
streptozocin  (ISO)
sunitinib  (ISO)
tamoxifen  (ISO)
teriflunomide  (ISO)
testosterone  (ISO)
tetrachloromethane  (EXP,ISO)
tetraphene  (ISO)
thimerosal  (ISO)
thymoquinone  (ISO)
titanium dioxide  (ISO)
trans-piceid  (ISO)
Tributyltin oxide  (ISO)
trichostatin A  (ISO)
triclosan  (ISO)
Triptolide  (EXP)
troglitazone  (ISO)
valproic acid  (ISO)
vinclozolin  (EXP)
vismodegib  (ISO)
vitamin E  (ISO)
vorinostat  (ISO)
WIN 55212-2  (ISO)
wortmannin  (ISO)
XAV939  (ISO)
zearalenone  (EXP,ISO)
zidovudine  (ISO)
zinc atom  (EXP)
zinc sulfate  (EXP)
zinc(0)  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
adult locomotory behavior  (ISO)
cell division  (IEA)
cellular response to dexamethasone stimulus  (IEP)
cellular response to follicle-stimulating hormone stimulus  (IEP)
cellular response to growth hormone stimulus  (IEP)
cellular response to insulin stimulus  (IEP)
cellular response to testosterone stimulus  (IEP)
cellular response to X-ray  (ISO)
G1/S transition of mitotic cell cycle  (IEP,IMP,ISO,NAS,TAS)
liver development  (IEP)
long-term memory  (ISO)
mitotic cell cycle phase transition  (IBA)
negative regulation of apoptotic process  (ISO)
negative regulation of cardiac muscle cell differentiation  (IDA)
ovarian follicle development  (IEP)
positive regulation of cardiac muscle cell proliferation  (IDA)
positive regulation of cell population proliferation  (IMP,ISO)
positive regulation of cyclin-dependent protein serine/threonine kinase activity  (ISO)
positive regulation of epithelial cell proliferation  (IMP)
positive regulation of G1/S transition of mitotic cell cycle  (ISO)
positive regulation of protein phosphorylation  (ISO)
regulation of cell cycle  (ISO)
regulation of cyclin-dependent protein serine/threonine kinase activity  (IBA)
regulation of neuron differentiation  (IEP)
response to cAMP  (IEP)
response to estradiol  (IEP)
response to estrogen  (IEP)
response to ethanol  (IEP)
response to follicle-stimulating hormone  (IEP)
response to human chorionic gonadotropin  (IEP)
response to organic cyclic compound  (IEP)
response to organic substance  (IEA)
response to peptide hormone  (IEP)
response to testosterone  (IEP)
spermatogenesis  (IEP)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype. Anwar SL, etal., PLoS One. 2019 May 6;14(5):e0216374. doi: 10.1371/journal.pone.0216374. eCollection 2019.
2. Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Bartkova J, etal., Gastroenterology. 2001 Jun;120(7):1680-8. doi: 10.1053/gast.2001.24880.
3. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Bergsagel PL, etal., Blood. 2005 Jul 1;106(1):296-303. Epub 2005 Mar 8.
4. D-type cyclins and G1 progression during liver development in the rat. Boylan JM and Gruppuso PA, Biochem Biophys Res Commun. 2005 May 13;330(3):722-30.
5. Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis. Chiara M, etal., Clin Exp Immunol. 2005 Feb;139(2):225-35.
6. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Chu S, etal., Mol Hum Reprod. 2002 May;8(5):426-33.
7. Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development. Diederichs S, etal., Int J Cancer. 2005 Aug 20;116(2):207-17.
8. 2,3,7,8-tetrachlorodibenzo-p-dioxin-dependent release from contact inhibition in WB-F344 cells: involvement of cyclin A. Dietrich C, etal., Toxicol Appl Pharmacol. 2002 Sep 1;183(2):117-26.
9. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Evron E, etal., Cancer Res. 2001 Mar 15;61(6):2782-7.
10. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Fackler MJ, etal., Int J Cancer. 2003 Dec 20;107(6):970-5.
11. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Faussillon M, etal., Cancer Lett. 2005 Apr 18;221(1):67-75.
12. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Friedrichsen BN, etal., Mol Endocrinol. 2003 May;17(5):945-58. doi: 10.1210/me.2002-0356. Epub 2003 Feb 13.
13. Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts. Fujita M, etal., Biochem Biophys Res Commun. 2002 Nov 29;299(2):222-8.
14. Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Fujiwara K, etal., Carcinogenesis. 2004 Aug;25(8):1495-505. Epub 2004 Apr 1.
15. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
16. Dexamethasone Induces Cardiomyocyte Terminal Differentiation via Epigenetic Repression of Cyclin D2 Gene. Gay MS, etal., J Pharmacol Exp Ther. 2016 Aug;358(2):190-8. doi: 10.1124/jpet.116.234104. Epub 2016 Jun 14.
17. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
18. The Vin-1 gene, identified by provirus insertional mutagenesis, is the cyclin D2. Hanna Z, etal., Oncogene 1993 Jun;8(6):1661-6.
19. miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). He X, etal., J Exp Clin Cancer Res. 2018 Sep 18;37(1):230. doi: 10.1186/s13046-018-0882-4.
20. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Henrique R, etal., J Mol Med. 2006 Nov;84(11):911-8. Epub 2006 Sep 22.
21. Induction of D2 and D3 cyclin-encoding genes during promotion of the G1/S transition by prolactin in rat Nb2 cells. Hosokawa Y, etal., Gene 1994 Sep 30;147(2):249-52.
22. Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target. Hung CS, etal., Int J Mol Sci. 2018 Oct 10;19(10). pii: ijms19103096. doi: 10.3390/ijms19103096.
23. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Ito M, etal., Clin Immunol. 2010 Jun;135(3):459-65. doi: 10.1016/j.clim.2010.02.002. Epub 2010 Mar 1.
24. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Jeronimo C, etal., Breast Cancer Res Treat. 2007 Jun 5;.
25. Long non-coding RNA JPX correlates with poor prognosis and tumor progression in non-small-cell lung cancer by interacting with miR-145-5p and CCND2. Jin M, etal., Carcinogenesis. 2020 Jul 10;41(5):634-645. doi: 10.1093/carcin/bgz125.
26. Inhibition of extracellular signal-regulated protein kinase-2 phosphorylation by dihydrotestosterone reduces follicle-stimulating hormone-mediated cyclin D2 messenger ribonucleic acid expression in rat granulosa cells. Kayampilly PP and Menon KM, Endocrinology. 2004 Apr;145(4):1786-93. Epub 2003 Dec 22.
27. Dihydrotestosterone inhibits insulin-stimulated cyclin D2 messenger ribonucleic acid expression in rat ovarian granulosa cells by reducing the phosphorylation of insulin receptor substrate-1. Kayampilly PP and Menon KM, Endocrinology. 2006 Jan;147(1):464-71. Epub 2005 Oct 6.
28. Effects of prenatal exposure to ethanol on the cyclin-dependent kinase system in the developing rat cerebellum. Li Z, etal., Brain Res Dev Brain Res. 2002 Dec 15;139(2):237-45.
29. Growth suppression by p16ink4 requires functional retinoblastoma protein. Medema RH, etal., Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93. doi: 10.1073/pnas.92.14.6289.
30. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Mehrotra J, etal., Clin Cancer Res. 2004 May 1;10(9):3104-9.
31. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
32. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
33. Promoter methylation of cyclin D2 gene in gastric carcinoma. Oshimo Y, etal., Int J Oncol. 2003 Dec;23(6):1663-70.
34. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. Park SY, etal., J Exp Clin Cancer Res. 2019 Sep 11;38(1):399. doi: 10.1186/s13046-019-1405-7.
35. CCND2 polymorphisms associated with clearance of HBV infection. Park TJ, etal., J Hum Genet. 2010 Jul;55(7):416-20. doi: 10.1038/jhg.2010.36. Epub 2010 Apr 23.
36. Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad. Park Y, etal., J Biol Chem. 2005 Mar 11;280(10):9135-48. doi: 10.1074/jbc.M409486200. Epub 2004 Dec 21.
37. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
38. Dihydrotestosterone inhibits granulosa cell proliferation by decreasing the cyclin D2 mRNA expression and cell cycle arrest at G1 phase. Pradeep PK, etal., Endocrinology 2002 Aug;143(8):2930-5.
39. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Pu RT, etal., Acta Cytol. 2006 Sep-Oct;50(5):499-506.
40. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Qian Y, etal., Med Sci Monit. 2020 Dec 15;26:e927444. doi: 10.12659/MSM.927444.
41. GOA pipeline RGD automated data pipeline
42. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
43. Comprehensive gene review and curation RGD comprehensive gene curation
44. Hormone-induced proliferation and differentiation of granulosa cells: a coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1. Robker RL and Richards JS, Mol Endocrinol. 1998 Jul;12(7):924-40.
45. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Rosenbaum E, etal., Clin Cancer Res. 2005 Dec 1;11(23):8321-5. doi: 10.1158/1078-0432.CCR-05-1183.
46. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. Sakuma M, etal., Cancer Sci. 2007 Mar;98(3):380-6.
47. Expression of cyclin D2 is an independent predictor of the development of hepatic metastasis in colorectal cancer. Sarkar R, etal., Colorectal Dis. 2010 Apr;12(4):316-23. doi: 10.1111/j.1463-1318.2009.01829.x. Epub 2009 Mar 11.
48. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Schmidt BA, etal., Cancer Res. 2001 May 15;61(10):4214-21.
49. The Pezcoller lecture: cancer cell cycles revisited. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
50. Prognostic significance of combined microRNA-206 and CyclinD2 in gastric cancer patients after curative surgery: A retrospective cohort study. Shi H, etal., Biomed Pharmacother. 2015 Apr;71:210-5. doi: 10.1016/j.biopha.2014.12.037. Epub 2015 Jan 9.
51. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Skotheim RI, etal., Cell Oncol. 2006;28(5-6):315-26.
52. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: implications for erectile dysfunction. Soh J, etal., Urology. 2007 Nov;70(5):1019-23.
53. Histological observation of the development of follicles and follicular atresia in immature rat ovaries. Takagi K, etal., Acta Med Okayama. 2007 Oct;61(5):283-98.
54. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Takano Y, etal., Am J Pathol. 2000 Feb;156(2):585-94. doi: 10.1016/S0002-9440(10)64763-3.
55. Differential expression of D type cyclins during neuronal maturation. Tamaru T, etal., Neurosci Lett. 1994 Feb 28;168(1-2):229-32.
56. Androgen regulation of stage-dependent cyclin D2 expression in Sertoli cells suggests a role in modulating androgen action on spermatogenesis. Tan KA, etal., Biol Reprod. 2005 May;72(5):1151-60. Epub 2005 Jan 19.
57. CyPA-CD147-ERK1/2-cyclin D2 signaling pathway is upregulated during rat left ventricular hypertrophy. Tang FC, etal., Sheng Li Xue Bao. 2015 Aug 25;67(4):393-400.
58. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. Tomoda T, etal., J Gastroenterol Hepatol. 2012 Apr;27(4):797-804. doi: 10.1111/j.1440-1746.2011.06948.x.
59. Gene expression profile changes and possible molecular subtypes in differentiated-type nonkeratinizing nasopharyngeal carcinoma. Wang S, etal., Int J Cancer. 2011 Feb 15;128(4):753-62. doi: 10.1002/ijc.25392.
60. microRNA-1297 Inhibits the Growth and Metastasis of Colorectal Cancer by Suppressing Cyclin D2 Expression. Wang Y, etal., DNA Cell Biol. 2017 Nov;36(11):991-999. doi: 10.1089/dna.2017.3829. Epub 2017 Sep 21.
61. Differential expression of cyclin D2 and cdc2 genes in proliferating and nonproliferating alveolar epithelial cells. Wu F, etal., Am J Respir Cell Mol Biol. 1995 Jan;12(1):95-103.
62. Orphan nuclear receptor NR4A1 is a negative regulator of DHT-induced rat preantral follicular growth. Xue K, etal., Mol Endocrinol. 2012 Dec;26(12):2004-15. doi: 10.1210/me.2012-1200. Epub 2012 Oct 1.
63. Gene expression profiling identifies a set of transcripts that are up-regulated inhuman testicular seminoma. Yamada S, etal., DNA Res. 2004 Oct 31;11(5):335-44.
64. Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Yang Z, etal., Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5539-48.
65. The 5D4 antibody (anti-cyclin D1/D2) related antigen: cytoplasmic staining is correlated to the progression of gastric cancer. Yasogawa Y, etal., Pathol Int. 1998 Sep;48(9):717-22. doi: 10.1111/j.1440-1827.1998.tb03972.x.
66. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Yu J, etal., Aliment Pharmacol Ther. 2001 Sep;15(9):1505-11. doi: 10.1046/j.1365-2036.2001.01038.x.
67. Expression of cyclin genes in human gastric cancer and in first degree relatives. Yu J, etal., Chin Med J (Engl). 2002 May;115(5):710-5.
Additional References at PubMed
PMID:7739547   PMID:8114739   PMID:8543804   PMID:11384971   PMID:11809706   PMID:12801993   PMID:16887120   PMID:18504428   PMID:18827403   PMID:18927218   PMID:19029821   PMID:19837876  
PMID:23109711   PMID:23349233   PMID:23714078   PMID:24130168   PMID:25450615   PMID:26657864   PMID:26840039  


Genomics

Comparative Map Data
Ccnd2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.24159,966,883 - 159,989,261 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl4159,962,363 - 159,989,495 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx4166,196,679 - 166,219,054 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.04161,979,585 - 162,001,961 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.04160,613,640 - 160,636,015 (-)NCBIRnor_WKY
Rnor_6.04159,674,885 - 159,697,207 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl4159,674,885 - 159,697,207 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.04231,905,449 - 231,927,999 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.44163,523,817 - 163,546,501 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.14163,768,752 - 163,791,437 (-)NCBI
Celera4148,681,937 - 148,704,301 (-)NCBICelera
Cytogenetic Map4q42NCBI
CCND2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38124,273,762 - 4,305,353 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl124,269,771 - 4,305,353 (+)EnsemblGRCh38hg38GRCh38
GRCh37124,382,928 - 4,414,519 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 36124,253,199 - 4,284,777 (+)NCBINCBI36Build 36hg18NCBI36
Build 34124,253,198 - 4,284,777NCBI
Celera126,004,961 - 6,036,590 (+)NCBICelera
Cytogenetic Map12p13.32NCBI
HuRef124,239,192 - 4,271,184 (+)NCBIHuRef
CHM1_1124,382,561 - 4,414,148 (+)NCBICHM1_1
T2T-CHM13v2.0124,280,521 - 4,312,135 (+)NCBIT2T-CHM13v2.0
Ccnd2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm396127,102,125 - 127,131,913 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl6127,102,125 - 127,129,156 (-)EnsemblGRCm39 Ensembl
GRCm386127,125,162 - 127,152,188 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl6127,125,162 - 127,152,193 (-)EnsemblGRCm38mm10GRCm38
MGSCv376127,075,726 - 127,101,066 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv366127,091,327 - 127,116,667 (-)NCBIMGSCv36mm8
Celera6128,802,274 - 128,827,610 (-)NCBICelera
Cytogenetic Map6F3NCBI
cM Map661.92NCBI
Ccnd2
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554132,083,351 - 2,103,430 (+)EnsemblChiLan1.0
ChiLan1.0NW_0049554132,083,351 - 2,108,450 (+)NCBIChiLan1.0ChiLan1.0
CCND2
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1124,309,272 - 4,340,893 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl124,309,272 - 4,335,551 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v0124,385,957 - 4,417,602 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
CCND2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12740,563,306 - 40,593,362 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2740,564,921 - 40,594,255 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha276,088,998 - 6,119,026 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.02740,919,385 - 40,949,416 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2740,919,385 - 40,950,262 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12740,857,202 - 40,887,247 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02740,832,370 - 40,862,362 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0275,499,635 - 5,529,695 (+)NCBIUU_Cfam_GSD_1.0
Ccnd2
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404945104,687,978 - 104,709,380 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049366064,474,749 - 4,496,810 (+)EnsemblSpeTri2.0
SpeTri2.0NW_0049366064,474,801 - 4,496,158 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
CCND2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl566,087,379 - 66,114,571 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1566,092,483 - 66,114,575 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2568,314,784 - 68,331,944 (-)NCBISscrofa10.2Sscrofa10.2susScr3
CCND2
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1114,307,419 - 4,339,003 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl114,307,401 - 4,333,661 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660633,904,650 - 3,936,230 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Ccnd2
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046248601,382,948 - 1,405,107 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046248601,383,015 - 1,405,107 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ccnd2
31 total Variants
miRNA Target Status

Confirmed Target Of
miRNA GeneMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Mir98rno-miR-98-5pMirtarbaseexternal_infoLuciferase reporter assay//Microarray//Northern blFunctional MTI21183740

Predicted Target Of
Summary Value
Count of predictions:29
Count of miRNA genes:29
Interacting mature miRNAs:29
Transcripts:ENSRNOT00000027084
Prediction methods:Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2316958Gluco58Glucose level QTL 5810blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)411320076180699135Rat
1576316Ept5Estrogen-induced pituitary tumorigenesis QTL 53.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)483428419177635233Rat
1358202Gluco11Glucose level QTL 112.40.02adipocyte glucose uptake trait (VT:0004185)absolute change in adipocyte glucose uptake (CMO:0000873)485379421167139601Rat
634335Anxrr16Anxiety related response QTL 167.22locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)493308457167139447Rat
737821Hcar9Hepatocarcinoma resistance QTL 93.7liver integrity trait (VT:0010547)volume of individual liver tumorous lesion (CMO:0001078)4109866907167139601Rat
1331759Hrtrt13Heart rate QTL 133.54628heart pumping trait (VT:2000009)heart rate (CMO:0000002)4110275411168266883Rat
724535Cm18Cardiac mass QTL 182.6heart mass (VT:0007028)calculated heart weight (CMO:0000073)4118856416163856416Rat
634347Hcar8Hepatocarcinoma resistance QTL 85.8liver integrity trait (VT:0010547)liver tumorous lesion area to total liver area ratio (CMO:0001075)4123143783168143783Rat
631683Bp116Blood pressure QTL 1160.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)4124303370169303370Rat
6478778Anxrr51Anxiety related response QTL 510.25384locomotor behavior trait (VT:0001392)measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957)4124778595169778595Rat
7411558Bw133Body weight QTL 13313.840.001body mass (VT:0001259)body weight gain (CMO:0000420)4125590636170590636Rat
61451Ciaa4CIA Autoantibody QTL 43.1blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)4126395976167139601Rat
737978Pia23Pristane induced arthritis QTL 235.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4131730738167139601Rat
631511Pia7Pristane induced arthritis QTL 74.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4131730738167139601Rat
1549827Scl46Serum cholesterol level QTL 463.5blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)4132396220177396220Rat
724558Plsm2Polydactyly-luxate syndrome (PLS) morphotypes QTL 20.0003hindlimb integrity trait (VT:0010563)hind foot phalanges count (CMO:0001949)4132422778177422778Rat
61422Cia13Collagen induced arthritis QTL 134.5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4132642577167139601Rat
2303623Vencon2Ventilatory control QTL 23.8respiration trait (VT:0001943)minute ventilation (CMO:0000132)4135204660180204660Rat
1578674Bmd12Bone mineral density QTL 123.8femur mineral mass (VT:0010011)compact volumetric bone mineral density (CMO:0001730)4135699135180699135Rat
2293659Bmd35Bone mineral density QTL 354.50.0001femur strength trait (VT:0010010)femoral neck ultimate force (CMO:0001703)4137755016181392681Rat
61362Oia2Oil induced arthritis QTL 20.001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4138503169173369699Rat
1298524Oia8Oil induced arthritis QTL 8joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4138503169173369699Rat
1331738Bp209Blood pressure QTL 2092.979arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)4138503169179293946Rat
6478718Anxrr34Anxiety related response QTL 340.00896locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4144639524182687754Rat
6478748Anxrr42Anxiety related response QTL 420.28008locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4144639524182687754Rat
6478754Anxrr43Anxiety related response QTL 430.14035locomotor behavior trait (VT:0001392)distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493)4144639524182687754Rat
6478693Anxrr32Anxiety related response QTL 320.00092locomotor behavior trait (VT:0001392)measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957)4144639524182687754Rat
6478700Anxrr33Anxiety related response QTL 330.00896locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4144639524182687754Rat
10401796Kidm48Kidney mass QTL 48kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)4145568712182687754Rat
634342Cia24Collagen induced arthritis QTL 244.5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4146565735175236377Rat
12798525Anxrr57Anxiety related response QTL 573.210.05locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4147278504167139601Rat
1582237Kidm34Kidney mass QTL 3440.0001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)4148090542168069246Rat
10053718Scort25Serum corticosterone level QTL 252.150.0097blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)4155561574182687754Rat
1300109Rf13Renal function QTL 133.91renal blood flow trait (VT:2000006)absolute change in renal blood flow rate (CMO:0001168)4157710145182687754Rat

Markers in Region
D4Wox47  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.24159,967,186 - 159,967,407 (+)MAPPERmRatBN7.2
Rnor_6.04159,675,189 - 159,675,409NCBIRnor6.0
Rnor_5.04231,927,475 - 231,927,695UniSTSRnor5.0
RGSC_v3.44163,524,121 - 163,524,341UniSTSRGSC3.4
Celera4148,682,241 - 148,682,461UniSTS
Cytogenetic Map4q42UniSTS
UniSTS:141259  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.24159,987,227 - 159,987,375 (+)MAPPERmRatBN7.2
Rnor_6.04159,695,174 - 159,695,321NCBIRnor6.0
Rnor_5.04231,907,335 - 231,907,482UniSTSRnor5.0
RGSC_v3.44163,544,468 - 163,544,615UniSTSRGSC3.4
Celera4148,702,268 - 148,702,415UniSTS
Cytogenetic Map4q42UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 43 45 29 19 29 6 6 70 30 35 11 6
Low 12 12 12 2 5 4 5 6 2
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000086440   ⟹   ENSRNOP00000073319
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl4159,674,885 - 159,697,207 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000095313   ⟹   ENSRNOP00000082822
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl4159,962,363 - 159,989,477 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000112906   ⟹   ENSRNOP00000079919
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl4159,962,949 - 159,989,495 (-)Ensembl
RefSeq Acc Id: NM_022267   ⟹   NP_071603
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.24159,966,883 - 159,989,261 (-)NCBI
Rnor_6.04159,674,885 - 159,697,207 (-)NCBI
Rnor_5.04231,905,449 - 231,927,999 (+)NCBI
RGSC_v3.44163,523,817 - 163,546,501 (-)RGD
Celera4148,681,937 - 148,704,301 (-)RGD
Sequence:
Reference Sequences
RefSeq Acc Id: NP_071603   ⟸   NM_022267
- UniProtKB: G3V8M9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000073319   ⟸   ENSRNOT00000086440
RefSeq Acc Id: ENSRNOP00000082822   ⟸   ENSRNOT00000095313
RefSeq Acc Id: ENSRNOP00000079919   ⟸   ENSRNOT00000112906
Protein Domains
Cyclin N-terminal

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q04827-F1-model_v2 AlphaFold Q04827 1-288 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:621083 AgrOrtholog
BioCyc Gene G2FUF-42948 BioCyc
Ensembl Genes ENSRNOG00000057710 Ensembl
  ENSRNOG00000062959 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000079919.1 UniProtKB/TrEMBL
  ENSRNOP00000082822 ENTREZGENE
  ENSRNOP00000082822.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000095313 ENTREZGENE
  ENSRNOT00000095313.1 UniProtKB/TrEMBL
  ENSRNOT00000112906.1 UniProtKB/TrEMBL
Gene3D-CATH Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Cyclin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_C-dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:64033 UniProtKB/Swiss-Prot
NCBI Gene 64033 ENTREZGENE
PANTHER PTHR10177 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10177:SF66 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Ccnd2 PhenoGen
PROSITE CYCLINS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART CYCLIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF47954 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I5ZPI7_RAT UniProtKB/TrEMBL
  CCND2_RAT UniProtKB/Swiss-Prot
  G3V8M9 ENTREZGENE, UniProtKB/TrEMBL
  Q04827 ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2008-01-24 Ccnd2  cyclin D2  Ccnd2_predicted  cyclin D2 (predicted)  Data Merged 737654 APPROVED
2005-01-12 Ccnd2_predicted  cyclin D2 (predicted)      Symbol and Name status set to approved 70820 APPROVED
2004-02-26 Ccnd2  cyclin D2      Symbol and Name status set to approved 625702 APPROVED
2002-08-07 Ccnd2  cyclin D2      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_regulation dihydrotestosterone (DHT), a 5-alpha reduced metabolite of testosterone, decreases mRNA expression and results in cell cyle arrest at G1 phase of granulosa cells 625716
gene_regulation expression altered by integration of proviruses in the Vin-1 common site of integration in retrovirus-induced rodent T-cell leukemias 724623